Aastrom banks $38M for pivotal study of cellular therapy

Aastrom Biosciences' ($ASTM) stock was up this morning after the developer announced a $40 million financing deal with Eastern Capital. The deal is expected to net $38 million after expenses, with a portion of the funds bankrolling the Ann Arbor, MI-based company's recently begun pivotal study of a cellular therapy called ixmyelocel-T for critical limb ischemia. MVL & Co. arranged the deal. Release

Suggested Articles

The deal gives J&J a stake in the development and commercialization of anticoagulants including phase 2-ready secondary stroke candidate BMS-986177.

Boehringer gained the global rights to OSE's SIRP-alpha antagonist, which is in development for solid tumors.

Lilly is diving into encapsulated beta cell treatments, designed to restore insulin production in patients with Type 1 diabetes.